SEASTAR MEDICAL HOLDING CORP (ICU) Stock Price, Quote, News and Overview
NASDAQ:ICU - Nasdaq - US81256L2034 - Common Stock - Currency: USD
ICU Quote, Performance and Key Statistics
1.25
0 (0%)
The current stock price of ICU is 1.25 USD. In the past month the price decreased by -43.44%. In the past year, price decreased by -88.64%.
ICU Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 27.16 | 225.18B | ||
| ISRG | INTUITIVE SURGICAL INC | 63.87 | 174.81B | ||
| BSX | BOSTON SCIENTIFIC CORP | 39.41 | 146.31B | ||
| SYK | STRYKER CORP | 29.3 | 136.31B | ||
| MDT | MEDTRONIC PLC | 15.68 | 107.41B | ||
| BDX | BECTON DICKINSON AND CO | 14.54 | 58.09B | ||
| EW | EDWARDS LIFESCIENCES CORP | 26.89 | 41.42B | ||
| IDXX | IDEXX LABORATORIES INC | 37.92 | 34.57B | ||
| RMD | RESMED INC | 24.26 | 31.49B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 14.45 | 29.71B | ||
| DXCM | DEXCOM INC | 40.52 | 26.22B | ||
| PHG | KONINKLIJKE PHILIPS NVR- NY | 15.38 | 22.99B |
Related stock screener links
About ICU
Company Profile
Seastar Medical Holding Corp. operates as a holding company whose subsidiaries manufacture and supply medical devices. The company is headquartered in Denver, Colorado and currently employs 12 full-time employees. The company went IPO on 2021-01-26. The firm is focused on developing extracorporeal therapies to reduce the consequences of hyperinflammation on vital organs. The firm's technologies rely on science to provide life-saving solutions to critically ill patients. The firm develops and commercializes cell-directed extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The firm uses its Selective Cytopheretic Device (SCD) technology platform to clinically validate several acute organ injury indications, including kidneys and lungs. Its investigational SCD is an extracorporeal synthetic membrane device designed to integrate into existing continuous renal replacement therapy (CRRT) systems that are commonly installed in hospitals throughout the United States.
Company Info
SEASTAR MEDICAL HOLDING CORP
3513 Brighton Blvd, Suite 410
Denver COLORADO US
Employees: 12
Company Website: https://seastarmedical.com
Investor Relations: https://investors.seastarmedical.com/overview/default.aspx
Phone: 18444278100
SEASTAR MEDICAL HOLDING CORP / ICU FAQ
What is the stock price of SEASTAR MEDICAL HOLDING CORP today?
The current stock price of ICU is 1.25 USD.
What is the ticker symbol for SEASTAR MEDICAL HOLDING CORP stock?
The exchange symbol of SEASTAR MEDICAL HOLDING CORP is ICU and it is listed on the Nasdaq exchange.
On which exchange is ICU stock listed?
ICU stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for SEASTAR MEDICAL HOLDING CORP stock?
5 analysts have analysed ICU and the average price target is 7.14 USD. This implies a price increase of 471.2% is expected in the next year compared to the current price of 1.25. Check the SEASTAR MEDICAL HOLDING CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is SEASTAR MEDICAL HOLDING CORP worth?
SEASTAR MEDICAL HOLDING CORP (ICU) has a market capitalization of 10.90M USD. This makes ICU a Nano Cap stock.
How many employees does SEASTAR MEDICAL HOLDING CORP have?
SEASTAR MEDICAL HOLDING CORP (ICU) currently has 12 employees.
What are the support and resistance levels for SEASTAR MEDICAL HOLDING CORP (ICU) stock?
SEASTAR MEDICAL HOLDING CORP (ICU) has a resistance level at 1.26. Check the full technical report for a detailed analysis of ICU support and resistance levels.
Is SEASTAR MEDICAL HOLDING CORP (ICU) expected to grow?
The Revenue of SEASTAR MEDICAL HOLDING CORP (ICU) is expected to grow by 358.72% in the next year. Check the estimates tab for more information on the ICU EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy SEASTAR MEDICAL HOLDING CORP (ICU) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ICU, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ICU, evaluating the profitability, health, valuation and growth aspects
- SEASTAR MEDICAL HOLDING CORP (ICU) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- SEASTAR MEDICAL HOLDING CORP (ICU) Sales and EPS estimates to see what analysts future expectations are.
- SEASTAR MEDICAL HOLDING CORP (ICU) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- SEASTAR MEDICAL HOLDING CORP (ICU) Insider and Institutional Ownership to learn about the owners and their transactions.
- SEASTAR MEDICAL HOLDING CORP (ICU) Stock Chart to make your own analysis
- SEASTAR MEDICAL HOLDING CORP (ICU) Latest news and press-releases to stay up to date.
Does SEASTAR MEDICAL HOLDING CORP (ICU) stock pay dividends?
ICU does not pay a dividend.
When does SEASTAR MEDICAL HOLDING CORP (ICU) report earnings?
SEASTAR MEDICAL HOLDING CORP (ICU) will report earnings on 2025-05-12.
What is the Price/Earnings (PE) ratio of SEASTAR MEDICAL HOLDING CORP (ICU)?
SEASTAR MEDICAL HOLDING CORP (ICU) does not have a PE ratio as the earnings reported over the last twelve months were negative (-7.78).
What is the Short Interest ratio of SEASTAR MEDICAL HOLDING CORP (ICU) stock?
The outstanding short interest for SEASTAR MEDICAL HOLDING CORP (ICU) is 4.21% of its float. Check the ownership tab for more information on the ICU short interest.
ICU Technical Analysis
ICU Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to ICU. Both the profitability and financial health of ICU have multiple concerns.
ICU Financial Highlights
Over the last trailing twelve months ICU reported a non-GAAP Earnings per Share(EPS) of -7.78. The EPS increased by 52.48% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -533.06% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
ICU Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 80% to ICU. The Buy consensus is the average rating of analysts ratings from 5 analysts.
For the next year, analysts expect an EPS growth of 80.14% and a revenue growth 358.72% for ICU